☆ 4.7 Article

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Microbiology

Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Wassihun Wedajo Aragaw et al.

Summary: Cyclohexyl-griselimycin, a preclinical candidate for treating tuberculosis, has shown activity against the drug-resistant Mycobacterium abscessus in vitro and in a mouse model. This discovery provides a new lead compound for M. abscessus drug development and supports the strategy of screening chemical matter from TB drug discovery to expedite the discovery of novel antibiotics against M. abscessus.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Critical Care Medicine

Treatment of Mycobacterium abscessus Pulmonary Disease

David E. Griffith et al.

Summary: Mycobacterium abscessus, a common pathogen in nontuberculous mycobacterial lung diseases, has different subspecies with varying drug susceptibilities. Macrolides and amikacin are commonly used drugs, but their efficacy is limited against resistant strains. New drugs show promising in vitro activity, but further validation is needed.

CHEST (2022)

添加到收藏夹

Editorial Material Immunology

Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue

Veronique Dartois et al.

Summary: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is currently treated with repurposed drugs that have limitations such as long chemotherapy duration, toxicity, parenteral administration, and low cure rates. There is a pressing need for more effective, tolerated, and oral antibiotics for the treatment of NTM-PD. Drawing lessons from tuberculosis treatment can aid in discovering curative oral regimens for NTM-PD.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

Paul B. Eckburg et al.

Summary: This study demonstrated the noninferiority of orally administered tebipenem pivoxil hydrobromide compared to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis, with similar safety profiles.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Biology

The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp

Elena Fernandez Alvaro et al.

Summary: The study identified the oral carbapenem Tebipenem as highly potent against Shigella, even multidrug-resistant variants. Additionally, synergistic drug combinations were found to reduce the risk of resistance development. Overall, Tebipenem shows promise as a potential treatment for severe diarrhoea caused by MDR Shigella and other enteric pathogens in low-middle income countries.

ELIFE (2022)

添加到收藏夹

Article Microbiology

Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease

Dereje A. Negatu et al.

Summary: This study screened the bioactive forms of oral beta-lactams against Mycobacterium abscessus in vitro, both with and without the bioactive form of the oral beta-lactamase inhibitor avibactam ARX1796. The results showed that sulopenem was equally effective without avibactam, while tebipenem, cefuroxime, and amoxicillin required avibactam for optimal activity. Furthermore, systematic pairing of the four beta-lactams revealed strong synergistic bactericidal effects when combined with amoxicillin in the presence of avibactam. These findings highlight the potential clinical value of these all-oral beta-lactam combinations.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Respiratory System

Trends in nontuberculous mycobacteria infection in children and young people with cystic fibrosis

Noreen Zainal Abidin et al.

Summary: Prevalence of NTM infection in pediatric CF patients remained substantially higher than in 2010 and was associated with allergic bronchopulmonary aspergillosis and Pseudomonas aeruginosa infection according to UK CF Registry data from 2016 to 2018.

JOURNAL OF CYSTIC FIBROSIS (2021)

添加到收藏夹

Letter Respiratory System

Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis

Dominic A. Hughes et al.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Review Chemistry, Medicinal

Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities

Anna Egorova et al.

Summary: This review discusses recent advances in novel small-molecule agents for M. abscessus, focusing on the activity, mode of action, and structure-activity relationship of promising inhibitors from different chemical classes. Additionally, it summarizes other interesting small molecules in early drug development stages and current knowledge about the efficacy of repurposable drugs.

MEDICINAL RESEARCH REVIEWS (2021)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Mycobacterium abscessus in cystic fibrosis

Rossa Brugha et al.

SCIENCE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Tebipenem pivoxil hydrobromide-No PICC, no problem!

Varun Sodhi et al.

Summary: Tebipenem pivoxil hydrobromide is a novel orally available prodrug with broad spectrum antimicrobial activity. Clinical trials have shown non-inferiority to intravenous antibiotics in treating urinary tract infections, with common adverse reactions including diarrhea, headache, and nausea. If approved, it could potentially reduce hospital stays and prevent admissions due to resistant pathogens.

PHARMACOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill

Tawanda Gumbo et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Review Microbiology

Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus

Matt D. Johansen et al.

NATURE REVIEWS MICROBIOLOGY (2020)

添加到收藏夹

Article Immunology

Outcome according to subspecies following lung transplantation in cystic fibrosis pediatric patients infected with Mycobacterium abscessus

Ema Kavaliunaite et al.

TRANSPLANT INFECTIOUS DISEASE (2020)

添加到收藏夹

Article Respiratory System

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

Charles L. Daley et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

Rebekah M. Dedrick et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors

Ryan L. Crass et al.

PHARMACOTHERAPY (2019)

添加到收藏夹

Article Microbiology

Teicoplanin - Tigecycline Combination Shows Synergy Against Mycobacterium abscessus

Dinah B. Aziz et al.

FRONTIERS IN MICROBIOLOGY (2018)

添加到收藏夹

Review Microbiology

Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities

Elizabeth Story-Roller et al.

FRONTIERS IN MICROBIOLOGY (2018)

添加到收藏夹

Article Chemistry, Medicinal

Orally Absorbed Derivatives of the beta-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs

Eric M. Gordon et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Microbiology

Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus

Amit Kaushik et al.

FUTURE MICROBIOLOGY (2017)

添加到收藏夹

Article Respiratory System

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis

Tavs Qvist et al.

JOURNAL OF CYSTIC FIBROSIS (2016)

添加到收藏夹

Article Infectious Diseases

β-Lactamase inhibition by avibactam in Mycobacterium abscessus

Vincent Dubee et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)

添加到收藏夹

Article Infectious Diseases

In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex

M. Lavollay et al.

CLINICAL MICROBIOLOGY AND INFECTION (2014)

添加到收藏夹

Editorial Material Respiratory System

Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Tavs Qvist et al.

RESPIRATORY RESEARCH (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084

Takeshi Isoda et al.

JOURNAL OF ANTIBIOTICS (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.